293 related articles for article (PubMed ID: 30257080)
1. Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia: A Meta-Analysis.
Mentzel TQ; van der Snoek R; Lieverse R; Oorschot M; Viechtbauer W; Bloemen O; van Harten PN
J Clin Psychiatry; 2018 Sep; 79(6):. PubMed ID: 30257080
[TBL] [Abstract][Full Text] [Related]
2. A systematic review on the use of clozapine in treatment of tardive dyskinesia and tardive dystonia in patients with psychiatric disorders.
Wong J; Pang T; Cheuk NKW; Liao Y; Bastiampillai T; Chan SKW
Psychopharmacology (Berl); 2022 Nov; 239(11):3393-3420. PubMed ID: 36180741
[TBL] [Abstract][Full Text] [Related]
3. Clozapine efficacy in tardive dyskinesia in schizophrenic patients.
Bassitt DP; Louzã Neto MR
Eur Arch Psychiatry Clin Neurosci; 1998; 248(4):209-11. PubMed ID: 9810484
[TBL] [Abstract][Full Text] [Related]
4. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug.
Li CR; Chung YC; Park TW; Yang JC; Kim KW; Lee KH; Hwang IK
World J Biol Psychiatry; 2009; 10(4 Pt 3):919-24. PubMed ID: 19995222
[TBL] [Abstract][Full Text] [Related]
5. Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review.
Pardis P; Remington G; Panda R; Lemez M; Agid O
J Psychopharmacol; 2019 Oct; 33(10):1187-1198. PubMed ID: 31347436
[TBL] [Abstract][Full Text] [Related]
6. Clozapine Treatment of Olanzapine-induced Tardive Dyskinesia: A Case Report.
Sangroula D; Virk I; Mohammad W; Kahn DA
J Psychiatr Pract; 2017 Jan; 23(1):53-59. PubMed ID: 28072646
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
[TBL] [Abstract][Full Text] [Related]
8. Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness: The Curaçao Extrapyramidal Syndromes Study XII.
Mentzel CL; Bakker PR; van Os J; Drukker M; Matroos GE; Hoek HW; Tijssen MA; van Harten PN
J Clin Psychiatry; 2017 Mar; 78(3):e279-e285. PubMed ID: 28199071
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.
Witter DP; Holbert RC; Suryadevara U
Expert Opin Pharmacother; 2017 Jul; 18(10):965-972. PubMed ID: 28443349
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Response to Clozapine and Its Clinical Correlates in the Treatment of Tardive Movement Syndromes: A Naturalistic Observational Study in Patients With Psychotic Disorders.
Lee D; Baek JH; Bae M; Choi Y; Hong KS
J Clin Psychopharmacol; 2019; 39(6):591-596. PubMed ID: 31688397
[TBL] [Abstract][Full Text] [Related]
12. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
McGrath JJ; Soares KV
Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
[TBL] [Abstract][Full Text] [Related]
13. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis.
Carbon M; Hsieh CH; Kane JM; Correll CU
J Clin Psychiatry; 2017 Mar; 78(3):e264-e278. PubMed ID: 28146614
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
[TBL] [Abstract][Full Text] [Related]
15. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
Seigneurie AS; Sauvanaud F; Limosin F
Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
[TBL] [Abstract][Full Text] [Related]
16. Tardive dyskinesia, clozapine, and treatment response.
Dalack GW; Becks L; Meador-Woodruff JH
Prog Neuropsychopharmacol Biol Psychiatry; 1998 May; 22(4):567-73. PubMed ID: 9682273
[TBL] [Abstract][Full Text] [Related]
17. Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial.
Diehl A; Reinhard I; Schmitt A; Mann K; Gattaz WF
Eur Psychiatry; 2009 Jan; 24(1):33-40. PubMed ID: 18774276
[TBL] [Abstract][Full Text] [Related]
18. Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: A case report.
Wietholter JP; Sizemore J; Piechowski K
Am J Health Syst Pharm; 2020 Sep; 77(18):1477-1481. PubMed ID: 32761113
[TBL] [Abstract][Full Text] [Related]
19. Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study.
Chan CH; Chan HY; Chen YC
Int Clin Psychopharmacol; 2018 May; 33(3):155-162. PubMed ID: 29324468
[TBL] [Abstract][Full Text] [Related]
20. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
Soares-Weiser K; Rathbone J
Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
